Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Aurinia Pharmaceuticals

Is Aurinia Pharmaceuticals Poised for Growth in the Biotech Space?

Aurinia Pharmaceuticals (AUPH) released its third-quarter results, reporting solid revenue growth and robust cash flow from operations. Solid demand for its product offerings, restructuring strategies, and sound financials remain key drivers of the company’s growth and success. So, let’s analyze whether AUPH is a buy today. Read more to find…

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022

PreMarket Prep Stock Of The Day: Good News From Aurinia Pharmaceuticals In A Down Week

PreMarket Prep Stock Of The Day: Good News From Aurinia Pharmaceuticals In A Down Week

Rarely mentioned in the recent chaos in the markets is the biotech sector. With a heavy emphasis in 2020 and 2021 on finding cures and treatments for COVID-19, major drug approvals from the FDA have been few and far between this year.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Earnings Preview For Aurinia Pharmaceuticals

Aurinia Pharmaceuticals (NASDAQ:AUPH) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Aurinia Pharmaceuticals will report an earnings per share (EPS) of $-0.27.

Analyst Ratings for Aurinia Pharmaceuticals

Analysts have provided the following ratings for Aurinia Pharmaceuticals (NASDAQ:AUPH) within the last quarter:

What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Aurinia Pharmaceuticals (NASDAQ:AUPH) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

1

Organisations

Arista Networks

Medical Pharmaceuticals

Petrobras Brasileiro

Lincoln National

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play